TAC Stock Recent News

TransAlta Corporation's shares have increased by 18.6% since May 31, with a strong investment case expected to continue. Recent power supply issues in Alberta may lead to more incentives for power generators, benefiting TransAlta. Despite lower Q2 results, TransAlta maintains its 2024 outlook, with a strong balance sheet and decreasing capital expenditures.

TransAlta (TAC) makes a strong case for investment, given its growth prospects, strong ROE and capability to increase shareholders' value.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

TransAlta Corporation (TAC) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, TAC's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.

The average of price targets set by Wall Street analysts indicates a potential upside of 63% in TransAlta (TAC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Q2 2024 and FY 2024 Key Highlights Q2 Financials - Beat on Revenues, ex-TAC and Adj. EBITDA; Growth rates accelerate Q2 2024 Results: Revenues $428M, Gross profit $115M, ex-TAC Gross Profit $150M, Net loss $4M, Non-GAAP Net Income $23M, Adj.

Patient enrollment has accelerated, now with 13 patients enrolled in trial TFF TAC at ~20% of the oral tacrolimus dose prevented acute rejection and achieved >80% of the previous oral trough blood levels -- leading to diminished drug burden 9 out of 9 (100%) patients who completed the 12-week treatment chose to remain on TFF TAC by proceeding to the long-term extension Phase; 2 patients have been treated for over a year and 6 patients have been treated for more than 6 months Observed a 6.5-fold reduction in the number of abnormally expressed rejection-related gene sets after treatment with TFF TAC No production of donor-specific antibodies (DSA) after treatment with TFF TAC FORT WORTH, Texas, Aug. 06, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today provided an update

TransAlta Corporation (NYSE:TAC ) Q2 2024 Earnings Conference Call August 1, 2024 11:00 AM ET Company Participants Chiara Valentini - VP, Strategic Finance & Investor Relations John Kousinioris - President & CEO Joel Hunter - EVP, Finance & CFO Blain Van Melle - EVP, Commercial & Customer Relations Conference Call Participants Patrick Kenny - National Bank Financial Mark Jarvi - CIBC Capital Markets Maurice Choy - RBC Capital Markets John Mould - TD Cowen Benjamin Pham - BMO Capital Markets Operator Good morning. My name is Amy, and I will be your conference operator today.

CALGARY, Alberta, Aug. 01, 2024 (GLOBE NEWSWIRE) -- TransAlta Corporation (“TransAlta” or the “Company”) (TSX: TA) (NYSE: TAC) today reported its financial results for the three and six months ended June 30, 2024, demonstrating strong financial performance and reaffirming its 2024 outlook.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.